Botulinum toxin a for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients

International Braz J Urol

Volumn 37, Issue 5, 2011, Pages 642-648

  Deffontaines Rufin, S ^a   Weil, M ^a   Verollet, D ^a   Peyrat, L ^a   Amarenco, G ^a  

^a HÔPITAL TENON   (France)

Author keywords

Administration; Botulinum toxins; Intravesical; Kidney; Multiple sclerosis; Neurogenic; Treatment outcome; Urinary bladder

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ARTICLE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; OVERACTIVE BLADDER; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URODYNAMICS;

BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 84860766098     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382011000500012     Document Type: Article

References (26)

1. Mallam E, Scolding N. The Diagnosis of MS. The International MS Journal. 2009; 16: 19-25.
2. Araki I, Matsui M, Ozawa K, Takeda M, Kuno S: Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003; 169: 1384-7.
3. Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Vespasiani G, Castellano V: Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn. 1998; 17: 89-98.
4. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21: 167-78.
5. Cohen BA: Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis. Neurology. 2008; 71(24 Suppl 3): S14-20.
6. Kennelly MJ, Devoe WB: Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol. 2008; 10: 182-91.
7. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B; GENULF: The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007; 13: 915-28.
8. DasGupta R, Fowler CJ: Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol. 2002; 15: 271-8.
9. MacDiarmid SA: How to choose the initial drug treatment for overactive bladder. Curr Urol Rep. 2007; 8: 364-9.
10. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al.: Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009; 55: 100-19.
11. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al.: Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005; 174: 196-200.
12. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M: Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004; 172: 240-3.
13. Gomes CM, Castro Filho JE, Rejowski RF, Trigo-Rocha FE, Bruschini H, Barros Filho TE, et al.: Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity. Int Braz J Urol. 2010; 36: 66-74.
14. Karsenty G, Denys P, Amarenco G, De Seze M, Gamé X, Haab F, et al.: Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008; 53: 275-87.
15. Toh KL, Tow A: Variation between clinical and urodynamical responses in patients receiving intradetrusor botulinum-A for refractory neurogenic detrusor overactivity. Urology 2007 70(Suppl 3A): 228. Abstract 01.122
16. Gamé X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudié I, De Boissezon X, Malavaud B, et al.: Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008; 53: 613-8.
17. Sahai A, Khan M, Fowler CJ, Dasgupta P: Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn. 2005; 24: 2-12.
18. Giannantoni A, Mearini E, Del Zingaro M, Santaniello F, Porena M: Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application. BJU Int. 2008; 102 (Suppl 1): 2-6.
19. Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiss C, Knispel HH: Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn. 2006; 25: 110-5.
20. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, et al.: Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007; 62: 452-7.
21. Mehnert U, Birzele J, Reuter K, Schurch B: The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010; 184: 1011-6.
22. Tow AM, Toh KL, Chan SP, Consigliere D: Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore. Ann Acad Med Singapore. 2007; 36: 11-7.
23. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000; 164: 692-7.
24. Patki PS, Hamid R, Arumugam K, Shah PJ, Craggs M: Botulinum toxin-type A in the treatment of drugresistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int. 2006; 98: 77-82.
25. Temeltas G, Tikiz C, Dagci T, Tuglu I, Yavasoglu A: The effects of botulinum-A toxin on bladder function and histology in spinal cord injured rats: is there any difference between early and late application? J Urol. 2005; 174: 2393-6.
26. Lekka E, Lee LK: Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol. 2006; 50: 806-9; discussion 809-10.